Cargando…
Prognostic factors for head and neck cancer of unknown primary including the impact of human papilloma virus infection
BACKGROUND: Head and neck cancer of unknown primary (HNCUP) is rare and prospective studies are lacking. The impact of different prognostic factors such as age and N stage is not completely known, the optimal treatment is not yet established, and the reported survival rates vary. In the last decade,...
Autores principales: | Axelsson, Lars, Nyman, Jan, Haugen-Cange, Hedda, Bove, Mogens, Johansson, Leif, De Lara, Shahin, Kovács, Anikó, Hammerlid, Eva |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5466757/ https://www.ncbi.nlm.nih.gov/pubmed/28601094 http://dx.doi.org/10.1186/s40463-017-0223-1 |
Ejemplares similares
-
Impact on quality of life of IMRT versus 3-D conformal radiation therapy in head and neck cancer patients: A case control study
por: Abel, Edvard, et al.
Publicado: (2017) -
Swedish National Multicenter Study on Head and Neck Cancer of Unknown Primary: Prognostic Factors and Impact of Treatment on Survival
por: Axelsson, Lars, et al.
Publicado: (2021) -
Bioelectrical phase angle at diagnosis as a prognostic factor for survival in advanced head and neck cancer
por: Axelsson, Lars, et al.
Publicado: (2018) -
Randomized Phase II Study with Cetuximab in Combination with 5-FU and Cisplatin or Carboplatin Vs. Cetuximab in Combination with Paclitaxel and Carboplatin for Treatment of Patients with Relapsed or Metastatic Squamous Cell Carcinoma of the Head and Neck (CETMET Trial)
por: Tsakonas, Georgios, et al.
Publicado: (2020) -
ARTSCAN III: A Randomized Phase III Study Comparing Chemoradiotherapy With Cisplatin Versus Cetuximab in Patients With Locoregionally Advanced Head and Neck Squamous Cell Cancer
por: Gebre-Medhin, Maria, et al.
Publicado: (2021)